Morgan Stanley upgrades Zealand Pharma to Buy on ’long-term obesity potential’
Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
PMLive6d
Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn
Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...
NBC Bay Area4d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Investors and patients will have to wait sometime for such products to launch, however, with Zealand Pharma's CEO and President Adam Steensberg telling CNBC that he expects Petrelintide to come to ...